Eurofins Discovery Announces Acquisition of DiscoveryBioMed

06 July 2022 | Wednesday | News

Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the acquisition of DiscoveryBioMed, a contract research organization (CRO) focused on developing novel human bioassays utilizing cells from diseased and normal human tissues.

Eurofins Discovery acquired DiscoveryBioMed for its expertise in leveraging primary and immortalized human diseased and normal cells to develop novel, customized bioassays supporting clients from HTS to lead optimization. DiscoveryBioMed achieves this through its focus on biologically relevant cellular models for the renal, skin, taste, ophthalmic, liver, respiratory, oncology, and other therapeutic areas.


The addition of DiscoveryBioMed supports Eurofins Discovery's strategy to have the most complete, highest quality portfolio of drug discovery services and products, and further strengthens its ability to support translational biology for drug discovery research and development.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in